Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy

Han,Wen‑Wen; Tang,Li‑Jun; Kong,Xiang‑Lei; Yang,Huan; Xu,Dong‑Mei

doi:10.3892/etm.2018.7108

Clinical significance of autoantibodies in the assessment and treatment of idiopathic membranous nephropathy

Authors:
- Wen‑Wen Han
- Li‑Jun Tang
- Xiang‑Lei Kong
- Huan Yang
- Dong‑Mei Xu
View Affiliations

Affiliations: Department of Clinical Medicine, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Nephrology, Qianfoshan Hospital, Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: December 18, 2018 https://doi.org/10.3892/etm.2018.7108
Pages: 1825-1830

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the correlation between the dynamic serum levels of phospholipase A2 receptor (PLA2R), aldose reductase (AR) and superoxide dismutase 2(SOD2) antibodies with disease activity and treatment response in patients with idiopathic membranous nephropathy (IMN). The present study included 56 patients with IMN who were diagnosed through a renal biopsy and presenting with nephrotic syndrome. The patients were divided into two treatment groups: One treated with cyclophosphamide (CTX) and one with tacrolimus (FK506). Serum was collected prior to treatment, and at 1, 3, 6, 9 and 12 months after the start of the 12‑month‑long therapy. Samples were tested by ELISA to measure anti‑PLA2R, anti‑AR and anti‑SOD2 antibody titers. In addition, urinary protein excretion, serum albumin (Alb) and other blood biochemical indexes were measured. Theanti‑PLA2R antibody positivity rate was 71.43% in the patients prior to treatment. After 12 months of treatment, proteinuria and PLA2R antibody levels were decreased, whereas serum Alb was increased. There was no significant difference of remission rates between the CTX and FK506 groups. In conclusion, the results of the present study indicate that the anti‑PLA2R antibody level is correlated with the severity of IMN, whereas anti‑AR and anti‑SOD2 antibody levels are not. In addition, there was no significant difference between the CTX and FK506 groups in regards to the remission rates of patients with IMN.

View Figures

View References

1	Ponticelli C: Membranous nephropathy. J Nephrol. 20:268–287. 2007.PubMed/NCBI
2	Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB and Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 361:11–21. 2009. View Article : Google Scholar : PubMed/NCBI
3	Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ and Liu Z.: Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 22:1137–1143. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF and Salant DJ: Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 6:1286–1291. 2011. View Article : Google Scholar : PubMed/NCBI
5	Prunotto M, Carnevali ML, Candiano G, Murtas C, Bruschi M, Corradini E, Trivelli A, Magnasco A, Petretto A, Santucci L, et al: Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 21:507–519. 2010. View Article : Google Scholar : PubMed/NCBI
6	Cattran DC, Feehally J, Cook HT, Liu ZH, Fervenza FC, Mezzano SA, Floege J, Nachman PH, Gipson DS, Praga M, et al: Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2:186–197. 2012.
7	Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, et al: Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol. 21:697–704. 2010. View Article : Google Scholar : PubMed/NCBI
8	Polanco N, Gutiérrez E, Rivera F, Castellanos I, Baltar J, Lorenzo D and Praga M: Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN): Spontaneous remission of nephritic syndrome in membranous nephropathy with chronic renal impairment. Nephrol Dial Transplant. 27:231–234. 2012. View Article : Google Scholar : PubMed/NCBI
9	Cattran D: Management of membranous nephropathy: When and what for treatment. J Am Soc Nephrol. 16:1188–1194. 2005. View Article : Google Scholar : PubMed/NCBI
10	Glassock RJ: Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 23:324–332. 2003. View Article : Google Scholar : PubMed/NCBI
11	Du Y, Li J, He F, Lv Y, Liu W, Wu P, Huang J, Wei S and Gao H: The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis. PLoS One. 9:e1049362014. View Article : Google Scholar : PubMed/NCBI
12	Bech AP, Hofstra JM, Brenchley PE and Wetzels JF: Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 9:1386–1392. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M, Poulton K, McWilliam L, Short CD, Venning M and Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 83:940–948. 2013. View Article : Google Scholar : PubMed/NCBI
14	Segarra-Medrano A, Jatem-Escalante E, Carnicer-Cáceres C, Agraz-Pamplona I, Salcedo MT, Valtierra N, Ostos-Roldán E, Arredondo KV and Jaramillo J: Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia. 34:491–497. 2014.(In English, Spanish). PubMed/NCBI
15	Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE and Wetzels JF: Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol. 23:1735–1743. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ponticelli C and Passerini P: Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy. J Nephrol. 23:156–163. 2010.PubMed/NCBI
17	Ronco P and Debiec H: Pathophysiological advances in membranous nephropathy: Time for a shift in patient's care. Lancet. 385:1983–1992. 2015. View Article : Google Scholar : PubMed/NCBI
18	Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, et al: Anti phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J Am Soc Nephrol. 26:2545–2558. 2015. View Article : Google Scholar : PubMed/NCBI
19	Liu H and Luo W: GONG Shaomin Detection and the clinical significance of phospholipase A2 receptor in idiopathic membranous nephropathy tissues. Fudan University Journal of Medical Sciences. 42:2015.